Predicting Cancer Cell Line Dependencies From the Protein Expression Data of Reverse-Phase Protein Arrays

Mei-Ju May Chen, PhD\(^1\); Jun Li, PhD\(^1\); Gordon B. Mills, MD, PhD\(^2\); and Han Liang, PhD\(^1\,3\)

PURPOSE Predicting cancer dependencies from molecular data can help stratify patients and identify novel therapeutic targets. Recently available data on large-scale cancer cell line dependency allow a systematic assessment of the predictive power of diverse molecular features; however, the protein expression data have not been rigorously evaluated. By using the protein expression data generated by reverse-phase protein arrays, we aimed to assess their predictive power in identifying cancer dependencies and to develop a related analytic tool for community use.

MATERIALS AND METHODS By using a machine learning schema, we conducted an analysis of feature importance based on cancer dependency and multiomic data from the DepMap and Cancer Cell Line Encyclopedia projects. We assessed the consistency of cancer dependency data between CRISPR/Cas9 and short hairpin RNA–mediated perturbation platforms. For a fair comparison, we focused on a set of genes with robust dependency data and four available expression-related features (copy number alteration, DNA methylation, messenger RNA expression, and protein expression) and performed the same-gene predictions of the cancer dependency using different molecular features.

RESULTS For the genes surveyed, we observed that the protein expression data contained substantial predictive power for cancer dependencies, and they were the best predictive feature for the CRISPR/Cas9-based dependency data. We also developed a user-friendly protein-dependency analytic module and integrated it with The Cancer Proteome Atlas; this module allows researchers to explore and analyze our results intuitively.

CONCLUSION This study provides a systematic assessment for predicting cancer dependencies of cell lines from different expression-related features of a gene. Our results suggest that protein expression data are a highly valuable information resource for understanding tumor vulnerabilities and identifying therapeutic opportunities.

INTRODUCTION
Understanding the genotype-phenotype relationships of cancer cells is a central task for precision cancer medicine because it will help classify patients into different treatment groups and identify novel therapeutic targets. The recent genome-wide short hairpin RNA (shRNA) or CRISPR/Cas9-mediated cell viability screens provide a unique opportunity to systematically characterize cancer dependencies in human cancer cell lines.\(^1\,3\) For example, the DepMap portal has curated the dependency profiles of approximately 18,000 genes across more than 500 human cell lines. Several studies have assessed the possibility of predicting cancer dependency from genomic or transcriptomic features.\(^5\,7\) Although proteins are basic functional units in most biologic processes and represent the vast majority of therapeutic targets, proteomic features have not been evaluated along with those DNA- or RNA-level features in such studies.

RPPAs are a powerful approach to generate functional proteomics data. This quantitative antibody-based assay can assess a large number of protein markers in many samples in a cost-effective, sensitive, and high-throughput manner.\(^5\,7\) By using RPPAs, we have characterized a large number of patient and cell line samples through The Cancer Genome Atlas,\(^8\,9\) Cancer Cell Line Encyclopedia (CCLE),\(^10\,13\) and MD Anderson Cell Line projects.\(^14\) Furthermore, we have built an open-access, dedicated bioinformatics resource, The Cancer Proteome Atlas (TCPA), for the cancer research community to study these large-scale functional proteomic data in a rich context.\(^14\,17\) Here, we used a rigorous machine learning (ML) schema to evaluate the cancer-dependency predictive power of the RPPA-based protein expression along with other expression-related molecular features (ie, copy number alteration [CNA], DNA methylation, and mRNA
expression). We also implemented a new protein-dependency analytic module in TCPA, thereby allowing users to explore, analyze, and visualize the relationships between protein expression and cancer dependency.

MATERIALS AND METHODS

Collection of RPPA, Cancer Dependency, and Other Molecular Profiling Data

We downloaded the RPPA data from the CCLE,10-13 which assayed 214 protein markers across 899 cell lines (https://portals.broadinstitute.org/ccle). We obtained cancer dependency data, including CRISPR/Cas9 (DepMap19Q1)2,18 and shRNA (DEMETER2)1 data sets, from the DepMap portal (https://depmap.org/portal). We also collected CNA, DNA methylation, and mRNA expression data from CCLE (https://portals.broadinstitute.org/ccle).

Model Outcome and Feature Engineering

We considered a regression task in dependency scores (cell growth change) that experienced gene knockdown

FIG 1. Data processing and the definition of the machine learning problem. (A) The procedure to obtain the final set that contains the data of the model outcome and all available features. (B) A cartoon representation of the cis-prediction (same gene) of cancer dependency from the four expression-related features, including protein (orange), messenger RNA (mRNA; blue), copy number alteration (CNA; yellow), and DNA methylation (green).
(shRNA) or knockout (CRISPR/Cas9). Specifically, the response variable (model outcome) is a vector of dependency scores for each gene across cell lines. A score of 0 indicates that a gene is not essential, whereas a score of −1 corresponds to the median value of all common essential genes. The explanatory variables (predictors) were the self-features that were related to gene expression. To ensure the quality of the model outcome, we first

![Diagram](image_url)

**FIG 2.** Overview of machine learning schema.

![Diagram](image_url)

**FIG 3.** Common dependencies between short hairpin RNA (shRNA) and CRISPR/Cas9 experiments from DepMap. (A) Venn diagram of cancer cell lines from the two sets. (B) Venn diagram of genes from the two sets. (C) Histogram of Pearson’s correlations across all genes for each cancer cell line (sample-wise correlation). (D) Histogram of Pearson’s correlations across cancer cell lines for each gene (gene-wise correlation). The significant correlations ($P < .01$, false discovery rate [FDR] < 0.1, and $R \geq 0.3$) are highlighted in red (C), and orange (D).
constructed a robust cancer dependency set by collecting genes and cell lines that showed high consistency between shRNA (DEMETER2) and CRISPR/Cas9 (DepMap19Q1) experiments. Next, this robust dependency set was overlapped with the cell lines and genes from CCLE to extract available data for model training (Fig 1A). To conduct a fair comparison, we considered only three expression-related DNA or RNA features (CNA, DNA methylation, and mRNA expression) with the RPPA-based protein expression data (total protein levels) from the same set of cell lines and performed cis-prediction (for the same gene) between the cancer dependency (response variable) and molecular features (explanatory variables) (Fig 1B).

ML Schema
As shown in Figure 2, the samples (cancer cell lines) were randomly split into a training set (70%) and a held-out testing set (30%). To test which ML algorithm performed best, we adopted three common classifiers: linear regression, random forest, and conditional random forest. We also conducted a baseline model to exclude failed predictions by using the averaged dependency score as the predicted values. For model training, we performed 10-fold cross validation using the training set and repeated the procedure 10 times to avoid model overfitting. Then, we applied the trained models on the held-out testing set. The prediction performance was measured and compared using the root-mean-square error (RMSE) and $R^2$. We trained models for each gene dependency. A dependency was flagged as predictable if it had at least one classifier that outperformed (had lower RMSE than) the baseline model in both the training and testing predictions. For the genes with predictable dependencies, we selected the best classifier (with the highest $R^2$) based on the testing results and used the selected classifier to retrain the model using all samples. Finally, to evaluate the individual contribution of each feature, we performed a feature importance analysis to identify the best predictor for each dependency. We implemented this ML schema in R v3.5.0 using the caret package19 with the ML methods of lm, rf, and cforest. In addition, we used the varImp function to estimate the feature importance.

Development of the Protein-Dependency Analytic Module
We used R and Python libraries to process and analyze the data. All the precomputed analytic results were converted into the JSON format and loaded into the CouchDB database for users to query and analyze. We used JavaScript D3 and the Angular library to construct the Web user interface of the protein-dependency analytic module. The module displays the table results by DataTables and the nested plots by HighCharts.

Data Sharing Statement
The data and results are available at the TCPA website (http://tcpaportal.org/mclp).
RESULTS

Construction of a Robust Cancer Dependency Data Set

To ensure the data quality of the cancer dependency scores, we constructed a robust cancer dependency set. The shRNA (DEMETER2) and CRISPR/Cas9 (DepMap19Q1) platforms shared 403 cancer cell lines and 14,913 genes (Fig 3A-B). We first evaluated the consistency between the two platforms by computing Pearson’s correlations across genes for each cell line (Fig 3C) and the correlations across cell lines for each gene (Fig 3D). The results showed that almost all the cell lines (99.8%, except for one) showed significant positive correlations of cross-platform cancer dependencies ($P < .01$; false discovery rate [FDR] < 0.1; $R \geq 0.3$). In contrast, only 862 genes (5.8%) showed significant positive correlations across cell lines ($P < .01$; FDR < 0.1; $R \geq 0.3$). This pattern suggested that many of the dependencies resulted from random effects and thus could not be preserved across the platforms. In subsequent analyses, we retained only 402 cell lines and 862 genes that showed significant consistency between the shRNA and CRISPR/Cas9 platforms to reduce potential random noise.

Predictive Power of Protein Expression in Cancer Dependency

On the basis of the designed ML schema (Fig 2), we assessed the predictive power for 58 genes in 312 cell lines for which all four expression-related features (CNA, DNA methylation, mRNA, and protein expression) were available. First, we excluded the unreliable predictions from the assessment. By comparing with the baseline models, we found that more than 60% of gene dependencies could be successfully predicted from self-expression–related features irrespective of the platform (CRISPR/Cas9, 65.52%, Fig 4A; shRNA, 63.79%, Fig 4B). The ML models learned
better from the CRISPR/Cas9 platform than from the shRNA platform. Next, among the genes with predictable dependencies, we investigated which feature was the most important in inferring cancer dependencies. As shown in Fig 5A, 38.5% of the dependencies could be best inferred by protein expression when using the CRISPR/Cas9 platform data, followed by CNA (28.2%), mRNA expression (20.5%), and DNA methylation (12.8%). But the pattern changed when using the shRNA-defined dependencies (Fig 5B); the best predictor was mRNA expression (40.5%), followed by protein expression (32.4%), CNA (18.9%), and finally DNA methylation (8.1%). We then investigated the importance score distributions of the four features (Fig 5; Appendix Tables A1 and A2) and found that, in both platforms, the importance of the protein expression feature could not be distinguished from that of the mRNA feature. Nor could the importance of the CNA feature be distinguished from that of the protein and mRNA features in the CRISPR/Cas9-defined dependencies, even though the CRISPR/Cas9 dependencies had been corrected for copy-number effect. The different patterns observed for the shRNA and CRISPR/Cas9-defined dependencies may be a result of certain fundamental technical issues. For example, the superior performance of the mRNA feature in shRNA-defined dependencies is likely caused by the knockdown effects targeting mRNAs. Despite the relatively small number of genes and proteins surveyed, our results suggest that RPPA-based protein expression data contain substantial predictive power for cancer dependencies, at least equivalent to RNA sequencing–based mRNA expression, and they perform best when using CRISPR/Cas9 dependencies.

**Newly Developed Protein-Dependency Analytic Module in TCPA**

The above results highlight the utility of RPPA-based proteomic data in understanding cancer phenotypes and identifying novel therapeutic targets. Therefore, we developed a protein-dependency analytic module and integrated it into the cell-line Web platform of TCPA. This user-friendly, interactive module allows researchers to explore, visualize, and analyze the relationships between the RPPA and cancer dependency data. We included two independent RPPA data sets\textsuperscript{10,14} for users to examine the protein-dependency relationships of interest with ease. The
module provides a straightforward, intuitive table view so that users can investigate whether the expression level of a protein is a good predictor for the corresponding cancer dependency across cancer cell lines (tested by Pearson’s correlation; visualized by scatter plots; Fig 6). The first column contains the protein markers, followed by the knockdown or knockout genes and their assessment platform (shRNA or CRISPR/Cas9) and then the corresponding statistic and P value.

DISCUSSION

In this study, we assessed the potential of RPPA-based protein expression to infer cancer dependencies through a rigorous ML-based feature importance analysis. To the best of our knowledge, this is the first systematic analysis to elucidate the predictive power of protein expression in inferring gene dependencies across a large number of cell lines. Our findings provide a strong rationale for incorporating protein expression data into the prediction tasks of cancer dependencies. One limitation of this study is the relatively small number of genes and proteins assessed, which limits the statistical power compared with other expression-related features. Our RPPA platform covers only approximately 200 protein markers, and we are in the process of expanding the protein list to approximately 500 proteins. We will revisit this topic when a larger RPPA data set becomes available. In addition to the dependency of its gene, the protein level likely helps predict the effects of other genes, and for such an analysis, a similar ML strategy equipped with advanced feature selection techniques is warranted. We also implemented a new analytic module in TCPA that can be used to directly analyze and visualize the relationships between protein expression and cancer dependencies across cancer cell lines. This module will help researchers discover novel genotype-phenotype patterns, generate testable hypotheses, and interpret biologic findings in a tumor context–dependent manner. We expect it to be a valuable bioinformatics tool for the cancer research community.

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/cci/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Gordon B. Mills

Stock and Other Ownership Interests: CATENA, SPINDLETOP VENTURES, SignalChem Biotech, Tarveda Therapeutics, ImmunoMet Therapeutics

Honoraria: Nuevolution, AstraZeneca, Tarveda Therapeutics, TESARO, Symphogen, PDX BioTech, ImmunoMet Therapeutics, Eli Lilly

Consulting or Advisory Role: AstraZeneca, SignalChem Biotech, Tarveda Therapeutics, Symphogen, Takeda/Millennium Pharmaceuticals, PDX BioTech, ImmunoMet Therapeutics, Eli Lilly

Research Funding: Adelson Medical Research Foundation, AstraZeneca, NanoString Technologies, Breast Cancer Research Foundation, Karus Therapeutics, Ovarian Cancer Research Foundation, Pfizer, Prospect Creek Foundation, Tarveda/Millennium Pharmaceuticals, Ionis Pharmaceuticals, ImmunoMet Therapeutics

Patents, Royalties, Other Intellectual Property: Homologous recombination deficiency assay to Myriad Genetics, digital spatial profiling technology patent with Nanostring

Travel, Accommodations, Expenses: AstraZeneca, Pfizer, Symphogen, Chrysalis Biomedical Advisors, ImmunoMet Therapeutics, MIPCC

Han Liang

Stock and Other Ownership Interests: Precision Scientific, Eagle Nebula

Consulting or Advisory Role: Precision Scientific, Eagle Nebula

Travel, Accommodations, Expenses: Precision Scientific, Eagle Nebula

No other potential conflicts of interest were reported.

ACKNOWLEDGMENT

We thank Kamalika Mohumdar for editorial assistance.
REFERENCES

1. McFarland JM, Ho ZV, Kugener G, et al: Improved estimation of cancer dependencies from large-scale RNAi screens using model-based normalization and data integration. Nat Commun 9:4610, 2018
2. Meyers RM, Bryan JG, McFarland JM, et al: Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells. Nat Genet 49:1779184, 2017
3. Tsherniak A, Vazquez F, Montgomery PG, et al: Defining a cancer dependency map. Cell 170:564-576.e16, 2017
4. Dharia NV, Malone C, Iniguez AB, et al: Defining a pediatric cancer dependency map. Cancer Res 78, 2018 (abstr 2352)
5. Hennessy BT, Lu Y, Gonzalez-Angulo AM, et al: A technical assessment of the utility of reverse phase protein arrays for the study of the functional proteome in non-microdissected human breast cancers. Clin Proteomics 6:129-151, 2010
6. Nishizuka S, Charboneau L, Young L, et al: Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc Natl Acad Sci U S A 100:14229-14234, 2003
7. Tibes R, Qiu Y, Lu Y, et al: Reverse phase protein array: Validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther 5:2512-2521, 2006
8. Cancer Genome Atlas Research Network, Weinstein JN, Collisson EA, et al: The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet 45:1113-1120, 2013
9. Akbani R, Ng PK, Werner HM, et al: A pan-cancer proteomic perspective on The Cancer Genome Atlas. Nat Commun 5:3887, 2014
10. Ghandi M, Huang FW, Jané-Valbuena J, et al: Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature 569:503-508, 2019
11. Cancer Cell Line Encyclopedia Consortium; Genomics of Drug Sensitivity in Cancer Consortium: Pharmacogenomic agreement between two cancer cell line data sets. Nature 528:84-87, 2015
12. Barretina J, Caponigro G, Stransky N, et al: The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483:603-607, 2012
13. Li H, Ning S, Ghandi M, et al: The landscape of cancer cell line metabolism. Nat Med 25:850-860, 2019
14. Li J, Zhao W, Akbani R, et al: Characterization of human cancer cell lines by reverse-phase protein arrays. Cancer Cell 31:225-239, 2017
15. Sheehan KM, Calvert VS, Kay EW, et al: Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol Cell Proteomics 4:346-355, 2005
16. Spurrier B, Ramalingam S, Nishizuka S: Reverse-phase protein lysate microarrays for cell signaling analysis. Nat Protoc 3:1796-1808, 2008
17. Lu Y, Ling S, Hegde AM, et al: Using reverse-phase protein arrays as pharmacodynamic assays for functional proteomics, biomarker discovery, and drug development in cancer. Semin Oncol 43:476-483, 2016
18. Broad Institute: DepMap, Achilles 19Q1 Public, fgshare, Dataset, 2019. https://doi.org/10.6084/m9.fgshare.7655150.v1
19. Kuhn M: Building predictive models in R using the caret package. J Stat Softw 28:05, 2008
FIG A1. Performance of the selected models in Figure 5. (A) Box plots of $R$ (Pearson’s correlations) stratified by model types. (B) Box plots of RMSE stratified by model types. RMSE, root-mean-square error; shRNA, short hairpin RNA.
**TABLE A1.** Top 10 Predictions for CRISPR/Cas9-Based Dependencies Ranked by $R^2$

| Gene   | CNA $R^2$ | Importance Score (%) | Methylation $r$ | mRNA Importance Score (%) | Protein Importance Score (%) |
|--------|-----------|----------------------|-----------------|--------------------------|----------------------------|
| GATA3  | 0.43      | 0                    | 0.00            | 2.68                     | 0.36                       | 100                         | -0.64                       | 54.46                       | -0.60                       |
| BCL2   | 0.43      | 0                    | -0.05           | 0.4                      | 0.17                       | 64.89                      | -0.54                       | 100                         | -0.59                       |
| CDKN1A | 0.34      | 0                    | 0.03            | 1.34                     | -0.05                      | 100                        | 0.53                        | 52.88                       | 0.37                        |
| TP53   | 0.27      | 21.23                | 0.04            | 0                        | -0.03                      | 15.37                      | -0.08                       | 100                         | -0.29                       |
| CCND1  | 0.26      | 11.49                | -0.14           | 13.45                    | 0.23                       | 100                        | -0.36                       | 0                           | 0.07                        |
| CCNE1  | 0.26      | 4.56                 | -0.23           | 0                        | 0.04                       | 69.16                      | -0.33                       | 100                         | -0.44                       |
| ERBB2  | 0.26      | 100                  | -0.38           | 0                        | 0.15                       | 97.34                      | -0.34                       | 68.82                       | -0.40                       |
| CDKN1A | 0.30      | 4.35                 | 0.06            | 0                        | -0.04                      | 100                        | 0.5                         | 14.59                       | 0.27                        |
| WWTR1  | 0.21      | 0                    | -0.13           | 53.62                    | 0.36                       | 36.78                      | -0.27                       | 100                         | -0.36                       |
| BCL2L1 | 0.20      | 0.92                 | -0.12           | 44.46                    | 0.34                       | 100                        | -0.42                       | 0                           | 0.19                        |

**NOTE.** The importance scores and Pearson’s correlation coefficients ($r$) were computed between cancer dependency and every feature. Abbreviations: CNA, copy number alteration; mRNA, messenger RNA.

**TABLE A2.** Top 10 Predictions for shRNA-Based Dependencies Ranked by $R^2$

| Gene   | CNA $R^2$ | Importance Score (%) | DNA Methylation $r$ | mRNA Importance Score (%) | Protein Importance Score (%) | r |
|--------|-----------|----------------------|---------------------|--------------------------|----------------------------|---|
| GATA3  | 0.43      | 0                    | -0.13               | 0.62                     | 0.33                       | 100                       | -0.69                       | 44.31                       | -0.63                       |
| TP53   | 0.35      | 12.48                | 0.08                | 0                        | 0.04                       | 49.24                     | 0.01                        | 100                         | -0.31                       |
| ERBB2  | 0.32      | 19.61                | -0.47               | 0                        | 0.03                       | 100                       | -0.58                       | 6.71                        | -0.43                       |
| CDKN1A | 0.30      | 4.35                 | 0.06                | 0                        | -0.04                      | 100                       | 0.5                         | 14.59                       | 0.27                        |
| CCND1  | 0.24      | 0                    | -0.19               | 6.02                     | 0.19                       | 100                       | -0.41                       | 12.31                       | -0.16                       |
| BCL2   | 0.24      | 0                    | -0.18               | 5.32                     | 0.2                        | 97.28                     | -0.35                       | 100                         | -0.44                       |
| MDM4   | 0.24      | 10.69                | -0.18               | 0                        | 0.12                       | 2.78                      | -0.21                       | 100                         | -0.42                       |
| CCNE1  | 0.23      | 42.18                | -0.34               | 0                        | 0.04                       | 91.3                      | -0.45                       | 100                         | -0.44                       |
| BCL2L1 | 0.23      | 6.1                  | -0.2                | 28.94                    | 0.34                       | 100                       | -0.44                       | 0                           | -0.21                       |
| BRAF   | 0.22      | 100                  | -0.32               | 0                        | -0.03                      | 3.76                      | -0.02                       | 0.71                        | 0.11                        |

**NOTE.** The importance scores and Pearson’s correlation coefficients were computed between cancer dependency and every feature. Abbreviations: CNA, copy number alteration; mRNA, messenger RNA; shRNA, short hairpin RNA.